Trial Profile
A phase II study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post Human Leuckocyte Antigen(HLA)-mismatched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 12 Jun 2014 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 13 Mar 2014 New trial record